Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omission of pre-transplant consolidation therapy in acute myeloid leukemia
IRCT2014081818842N1Phase 3Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Primary endpoints: Disease-free survival, Overall survival and 1 more. Started Nov 2011; status: completed.
02
Drugs
cytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT2014081818842N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014081818842N1.